Histological and molecular evaluation of patient-derived colorectal cancer explants

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Uronis, Joshua M ^a   Osada, Takuya ^b   McCall, Shannon ^b   Yang, Xiao Yi ^b   Mantyh, Christopher ^b   Morse, Michael A ^b   Lyerly, H Kim ^b   Clary, Bryan M ^b   Hsu, David S ^a,b  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR CDX2; B RAF KINASE; BRAF PROTEIN, HUMAN; CDX2 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAF GENE; CANCER MODEL; CANCER TISSUE; CANCER TRANSPLANTATION; COLORECTAL CANCER; CONTROLLED STUDY; EXPLANT; GENE EXPRESSION PROFILING; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; ONCOGENE K RAS; PATIENT DERIVED COLORECTAL CANCER EXPLANT; ANIMAL; CELL NUCLEUS; COLORECTAL TUMOR; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; PATHOLOGY;

MUS;

ANIMALS; CELL NUCLEUS; COLORECTAL NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MICE; MUTATION; ONCOGENES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861842895     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038422     Document Type: Article

References (21)

1. Mnejja M, Hammami B, Bougacha L, Jemal L, Chakroun N, et al. (2011) Internal jugular vein thrombosis by protein C activated resistance. Eur Ann Otorhinolaryngol Head Neck Dis 128: 269-271.
2. Uronis JM, Threadgill DW, (2009) Murine models of colorectal cancer. Mamm Genome 20: 261-268.
3. Richmond A, Su Y, (2008) Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech 1: 78-82.
4. Druckrey H, Preussmann R, Matzkies F, Ivankovic S, (1967) [Selective production of intestinal cancer in rats by 1,2-dimethylhydrazine]. Naturwissenschaften 54: 285-286.
5. Papanikolaou A, Wang QS, Delker DA, Rosenberg DW, (1998) Azoxymethane-induced colon tumors and aberrant crypt foci in mice of different genetic susceptibility. Cancer Lett 130: 29-34.
6. Kaiser S, Park YK, Franklin JL, Halberg RB, Yu M, et al. (2007) Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol 8: R131.
7. Kerbel RS, (2003) Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2: S134-139.
8. Kendall SD, Adam SJ, Counter CM, (2006) Genetically engineered human cancer models utilizing mammalian transgene expression. Cell Cycle 5: 1074-1079.
9. Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA, (2006) Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 116: 1955-1962.
10. Harris LG, Samant RS, Shevde LA, (2011) Hedgehog signaling: networking to nurture a promalignant tumor microenvironment. Mol Cancer Res 9: 1165-1174.
11. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, et al. (2007) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13: 3989-3998.
12. Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, et al. (2008) Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 14: 6456-6468.
13. Pretlow TG, Wolman SR, Micale MA, Pelley RJ, Kursh ED, et al. (1993) Xenografts of primary human prostatic carcinoma. J Natl Cancer Inst 85: 394-398.
14. Arcaroli JJ, Touban BM, Tan AC, Varella-Garcia M, Powell RW, et al. (2010) Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer. Clin Cancer Res 16: 4165-4177.
15. Dangles-Marie V, Pocard M, Richon S, Weiswald LB, Assayag F, et al. (2007) Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res 67: 398-407.
16. Fichtner I, Slisow W, Gill J, Becker M, Elbe B, et al. (2004) Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 40: 298-307.
17. Kim M, Osada T, Barry WT, Yang X, Freedman JA, et al. (2012) Characterization of an Oxaliplatin Sensitivity Predictor in a preclinical Murine Model of Colorectal Cancer. Molecular Cancer Therapeutics in press.
18. Johnson WE, Li C, Rabinovic A, (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8: 118-127.
19. Adelstein BA, Dobbins TA, Harris CA, Marschner IC, Ward RL, (2011) A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer. Eur J Cancer 47: 1343-1354.
20. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, et al. (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697-4705.
21. Mischek D, Steinborn R, Petznek H, Bichler C, Zatloukal K, et al. (2009) Molecularly characterised xenograft tumour mouse models: valuable tools for evaluation of new therapeutic strategies for secondary liver cancers. J Biomed Biotechnol 2009 437284.